Roche’s incoming CEO and new pharma division leader will face shrinking revenues in 2023 as the company’s COVID-19 dividend fades. However, while investors may be keen for major changes to boost long-term growth, it is as yet unclear what strategic moves are planned.
The Basel, Switzerland-based company has been one of the sector’s top performers for a decade but saw its growth dip to just 1% in 2022 to CHF6.32bn ($69
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?